96 related articles for article (PubMed ID: 3547951)
1. Cytogenetic evidence of partial chimerism after T cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients.
Berthéas MF; Mascret B; Maraninchi D; Lafage M; Blaise D; Fraisse J; Brizard CP; Carcassonne Y; Mawas C
Transplant Proc; 1987 Feb; 19(1 Pt 3):2738-40. PubMed ID: 3547951
[No Abstract] [Full Text] [Related]
2. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect.
Henslee PJ; Thompson JS; Romond EH; Doukas MA; Metcalfe M; Marshall ME; MacDonald JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):2701-6. PubMed ID: 3547948
[No Abstract] [Full Text] [Related]
3. Partial chimerism after T-cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation.
Bertheas MF; Maraninchi D; Lafage M; Fraisse J; Blaise D; Stoppa AM; Michel G; Brizard CP; Gaspard MH; Novakovitch G
Blood; 1988 Jul; 72(1):89-93. PubMed ID: 3291987
[TBL] [Abstract][Full Text] [Related]
4. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
5. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in patients with leukemia].
Löwenberg B; Sizoo W; Wagemaker G; Sintnicolaas K; Hendriks WD; Hagenbeek A
Ned Tijdschr Geneeskd; 1986 May; 130(19):872-6. PubMed ID: 3520349
[No Abstract] [Full Text] [Related]
8. One haplotype matched bone marrow grafts: an investigation using the HLA system as a marker of cellular origin.
Jones EH; Lawler SD; Powles RL
Dis Markers; 1988 Mar; 6(1):47-55. PubMed ID: 3293882
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
10. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.
Bozdech MJ; Sondel PM; Trigg ME; Longo W; Kohler PC; Flynn B; Billing R; Anderson SA; Hank JA; Hong R
Exp Hematol; 1985 Dec; 13(11):1201-10. PubMed ID: 3905427
[TBL] [Abstract][Full Text] [Related]
11. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
12. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
[No Abstract] [Full Text] [Related]
14. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
Trigg ME; Sondel PM; Billing R; Finlay JL; Peterson A; Hong R; Frierdich S; Shahidi N
J Biol Response Mod; 1985 Dec; 4(6):602-12. PubMed ID: 3910764
[TBL] [Abstract][Full Text] [Related]
15. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
18. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
[No Abstract] [Full Text] [Related]
19. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
20. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R
Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
